Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Equity Ratio (2016 - 2025)

Zevra Therapeutics' Equity Ratio history spans 11 years, with the latest figure at 0.54 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 143.92% year-over-year to 0.54; the TTM value through Dec 2025 reached 0.54, up 143.92%, while the annual FY2025 figure was 0.54, 143.92% up from the prior year.
  • Equity Ratio reached 0.54 in Q4 2025 per ZVRA's latest filing, up from 0.49 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 823.37 in Q3 2022 to a low of 232.94 in Q2 2022.
  • Average Equity Ratio over 5 years is 31.71, with a median of 0.54 recorded in 2025.
  • The largest YoY upside for Equity Ratio was 85643.02% in 2022 against a maximum downside of 24844.23% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.76 in 2021, then fell by 14.83% to 0.65 in 2022, then plummeted by 44.88% to 0.36 in 2023, then tumbled by 37.97% to 0.22 in 2024, then soared by 143.92% to 0.54 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Equity Ratio are 0.54 (Q4 2025), 0.49 (Q3 2025), and 0.46 (Q2 2025).